Comparative Pharmacology
Head-to-head clinical analysis: EFINACONAZOLE versus FLUCYTOSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFINACONAZOLE versus FLUCYTOSINE.
EFINACONAZOLE vs FLUCYTOSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Efinaconazole inhibits fungal lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Flucytosine is a prodrug that is converted intracellularly to 5-fluorouracil (5-FU) by cytosine deaminase, an enzyme present in susceptible fungi. 5-FU is further metabolized to 5-fluorouridine triphosphate, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Apply a thin layer to affected area once daily for 2 weeks.
50-150 mg/kg/day orally divided every 6 hours. For cryptococcosis, 100 mg/kg/day in 4 divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 29 hours (range 22-36 hours), supporting once-daily dosing.
Clinical Note
moderateFlucytosine + Tranilast
"The risk or severity of adverse effects can be increased when Flucytosine is combined with Tranilast."
Clinical Note
moderateEfinaconazole + Tranilast
"The risk or severity of adverse effects can be increased when Efinaconazole is combined with Tranilast."
Clinical Note
moderateFlucytosine + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Flucytosine is combined with Tolfenamic acid."
Clinical Note
moderateTerminal elimination half-life is 3-6 hours in patients with normal renal function. In renal impairment (CrCl <40 mL/min), half-life extends to 50-100 hours, requiring dose adjustment.
Approximately 1.6% of the dose is excreted unchanged in urine; the remainder is eliminated via feces (63.7%) and urine (28.5%) as metabolites, with biliary excretion playing a major role.
Approximately 80-90% of a dose is excreted unchanged in the urine via glomerular filtration. Less than 10% is metabolized to 5-fluorouracil. Fecal excretion is minimal (<4%). No significant biliary excretion.
Category C
Category C
Antifungal Agent
Antifungal Agent
Efinaconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Efinaconazole is combined with Tolfenamic acid."